Thrombus Inhibitor
· Adjuvant to “Clot busting” therapeutics. · Method to prevent and/or treat cardiovascular/thrombotic disease. · Method to treat patients undergoing invasive cardiovascular procedures (e.g., angioplasty) · Aegyptin inhibits thrombosis in its early stages by preventing collagen interation with the three major ligands involved in thrombus/clot formation
Available for licensing is a collagen binding protein, named aegyptin, isolated from the salivary glands of the mosquito. Aegyptin selectively inhibits collagen-platelet aggregation, but not platelet aggregation induced by other agonists. In a collaboration between UCI and the NIH, scientists have functionally characterized aegyptin, demonstrating it blocks the interaction of collagen with its major ligands, von Willebrand factor, glycoprotein VI (GPVI), and integrin α2β1. These three ligands are of significant importance because they play a critical role in the early stages of thrombus formation, therefore aegyptin represents a potentially highly effective therapeutic to treat patients with thrombotic disease. Alternatively, aegypin is potentially useful in conditions where collagen plays a critical role in angiogenesis or in conditions where excessive deposition of collagen plays a pathological role (i.e., pancreatic carcinoma).
Patent Number: US8383589B2
Application Number: US2010668177A
Inventor: Calvo, Eric | Marinotti, Osvaldo | Ribeiro, Jose M. C. | Francischetti, Ivo M.
Priority Date: 9 Jul 2007
Priority Number: US8383589B2
Application Date: 7 Jan 2010
Publication Date: 26 Feb 2013
IPC Current: A61K003800 | A61K003836
US Class: 5140138 | 5140135 | 5140137
Assignee Applicant: The United States of America as represented by the Secretary Department of Health and Human Servicesshington | Regents of the University of California,Oakland
Title: Aegyptin and uses thereof
Usefulness: Aegyptin and uses thereof
Summary: The Aegyptin polypeptide, nucleic acid encoding Aegyptin polypeptide, antibody capable of specifically binding to an Aegyptin protein, and composition are useful for disrupting platelet adhesion, for reducing clot formation, for preventing metastasis, for treating or inhibiting progression of a malignant tumor, and for treating a thrombogenic disease selected from coronary thrombosis, pulmonary embolism, myocardial infarction, deep vein thrombosis, cerebral thrombosis, unstable angina, disseminated intravascular coagulation (DIC), postoperative fibrinolytic shutdown, or a rapid thrombogenic action which can occur following implantation of a medical device (all claimed).
Novelty: New nucleic acid encoding Aegyptin polypeptide, useful for treating or inhibiting progression of a malignant tumor and for treating a thrombogenic disease
Disease Diagnostic/Treatment
Cancer/Tumor
8383589
Publication Tech ID/UC Case 22973/2010-773-0 Related Cases 2010-773-0
USA
